A Phase 3 interventional study of Trastuzumab deruxtecan and Capecitabine in Breast Cancer, sponsored by Daiichi Sankyo. Completed at 227 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 6 that started in 2018, is one of 12 in phase 3, and was the 4th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
SOLTI Breast Cancer Research Group · Sites in France, Germany, Spain
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 37 · Phase 3 12 · Phase 4 2
First in 2017; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 608 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 139 across the 58 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 58 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
24 studies in Breast Neoplasms by Daiichi Sankyo: 6 open now, 8 under way, 3 of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 24 studies in Breast Neoplasms by Daiichi Sankyo, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 3, and was the 7th registered.
Daiichi Sankyo’s Breast Neoplasms studies by the year they started, since 1999.
13 of the studies testing trastuzumab deruxtecan in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05950945Phase 3Daiichi SankyoTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | 2027-10-01 |
| NCT06048718MedSIRT-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | 2026-11 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06486883MedSIRSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, from their registry updates:
Among Daiichi Sankyo’s 24 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will compare DS 8201a to standard treatment.
Participants must have HER2 breast cancer that has been treated before.
Their cancer:
The study is designed to compare DS 8201a versus standard of care (investigator's choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has documented breast cancer that:
Male and female participants of reproductive/ must agree to use a highly effective form of or avoid intercourse during and upon completion of the study and for at least:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
Drug: Trastuzumab deruxtecan
HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
Drug: Capecitabine · Drug: Trastuzumab
HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
Drug: Capecitabine · Drug: Lapatinib
DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
Also known as: DS-8201a, T-DXd
Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
Also known as: Investigator's Choice Comparative Therapy
Investigator's choice Standard of Care when combined with capecitabine
Also known as: Investigator's Choice Comparative Therapy
Investigator's choice Standard of Care when combined with capecitabine
Also known as: Investigator's Choice Comparative Therapy
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Progression-free survival (PFS) by BICR was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.
Time frame: Baseline up to 46 months postdose
Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.
Time frame: Baseline up to 46 months postdose
Percentage of Participants With Objective Response Rate (ORR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on BICR and Investigator Assessment is reported.
Time frame: Baseline up to 46 months postdose
Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.
Time frame: Baseline up to 46 months postdose
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Progression-free survival (PFS) by investigator assessment was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.
Time frame: Up to 46 months
A total of 608 participants were enrolled at study sites in 15 countries. Primary results reported is from first participant randomized up to data cut-off date of 30 Jun 2022. The results presented are based on primary analysis up to 46 months.
| Milestone | Trastuzumab Deruxtecan (T-DXd) | Trastuzumab+Capecitabine | Lapatinib+Capecitabine |
|---|---|---|---|
| Started | 406 | 91 | 111 |
| Randomized | 406 | 91 | 111 |
| Randomized but not treated | 2 | 4 | 3 |
| Completed | 94 | 1 | 4 |
| Not completed | 312 | 90 | 107 |
| Withdrew: Progressive disease | 174 | 64 | 77 |
| Withdrew: Adverse event | 74 | 5 | 9 |
| Withdrew: Withdrawal by subject | 30 | 11 | 6 |
| Withdrew: Clinical progression | 23 | 5 | 10 |
| Withdrew: Death | 4 | 0 | 1 |
| Withdrew: Physician decision | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Miscellaneous | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 1 |
| Withdrew: Randomized but not treated | 2 | 4 | 3 |
Progression-free survival (PFS) by BICR was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.
| months | Trastuzumab Deruxtecan (T-DXd) | Treatment of Investigator's/Physician's Choice (TPC) |
|---|---|---|
| Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine | 17.8 (14.3 to 20.8) | 6.9 (5.5 to 8.4) |
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.
| months | Trastuzumab Deruxtecan (T-DXd) | Treatment of Investigator's/Physician's Choice (TPC) |
|---|---|---|
| Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine | 39.2 (32.7 to NA) | 26.5 (21.0 to NA) |
The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on BICR and Investigator Assessment is reported.
| Percentage of Participants | Trastuzumab Deruxtecan (T-DXd) | Treatment of Investigator's/Physician's Choice (TPC) |
|---|---|---|
| BICR | 69.7 (65.0 to 74.1) | 29.2 (23.0 to 36.0) |
| Investigator Assessment | 74.1 (69.6 to 78.3) | 26.7 (20.8 to 33.4) |
Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.
| months | Trastuzumab Deruxtecan (T-DXd) | Treatment of Investigator's/Physician's Choice (TPC) |
|---|---|---|
| Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine | 19.6 (15.9 to NA) | 8.3 (5.8 to 9.5) |
Progression-free survival (PFS) by investigator assessment was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.
| months | Trastuzumab Deruxtecan (T-DXd) | Treatment of Investigator's/Physician's Choice (TPC) |
|---|---|---|
| Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine | 16.7 (14.3 to 19.6) | 5.5 (4.4 to 7.0) |
Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up 46 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab Deruxtecan (T-DXd) | 143/406 (35.2%) | 103/404 (25.5%) | 398/404 (98.5%) |
| Trastuzumab+Capecitabine | 40/91 (44%) | 19/87 (21.8%) | 79/87 (90.8%) |
| Lapatinib+Capecitabine | 46/111 (41.4%) | 27/108 (25%) | 102/108 (94.4%) |
| Event | Trastuzumab Deruxtecan (T-DXd) | Trastuzumab+Capecitabine | Lapatinib+Capecitabine |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/404 | 3/87 | 1/108 |
| Abdominal PainGastrointestinal disorders | 2/404 | 3/87 | 0/108 |
| Disease ProgressionGeneral disorders | 1/404 | 1/87 | 3/108 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 2/404 | 1/87 | 3/108 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 10/404 | 0/87 | 1/108 |
| VomitingGastrointestinal disorders | 6/404 | 2/87 | 0/108 |
| NauseaGastrointestinal disorders | 5/404 | 2/87 | 0/108 |
| PneumoniaInfections and infestations | 6/404 | 0/87 | 1/108 |
| PyrexiaGeneral disorders | 3/404 | 1/87 | 0/108 |
| GastroenteritisInfections and infestations | 1/404 | 1/87 | 1/108 |
| Event | Trastuzumab Deruxtecan (T-DXd) | Trastuzumab+Capecitabine | Lapatinib+Capecitabine |
|---|---|---|---|
| NauseaGastrointestinal disorders | 292/404 | 29/87 | 44/108 |
| DiarrhoeaGastrointestinal disorders | 109/404 | 33/87 | 69/108 |
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 7/404 | 48/87 | 52/108 |
| VomitingGastrointestinal disorders | 150/404 | 9/87 | 14/108 |
| AlopeciaSkin and subcutaneous tissue disorders | 150/404 | 4/87 | 4/108 |
| FatigueGeneral disorders | 144/404 | 20/87 | 32/108 |
| ConstipationGastrointestinal disorders | 142/404 | 12/87 | 9/108 |
| Decreased AppetiteMetabolism and nutrition disorders | 124/404 | 15/87 | 20/108 |
| AnaemiaBlood and lymphatic system disorders | 114/404 | 13/87 | 13/108 |
| AstheniaGeneral disorders | 97/404 | 6/87 | 13/108 |
Baseline characteristics were assessed using the Full Analysis Set.
| Age, Categorical(Participants) | Trastuzumab Deruxtecan (T-DXd) | Trastuzumab+Capecitabine | Lapatinib+Capecitabine | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 321 | 73 | 91 | 485 |
| >=65 years | 85 | 18 | 20 | 123 |
| Age, Continuous(years) | Trastuzumab Deruxtecan (T-DXd) | Trastuzumab+Capecitabine | Lapatinib+Capecitabine | Total |
|---|---|---|---|---|
| Mean | 54.6 ± 11.99 | 55.7 ± 11.40 | 54.6 ± 11.06 | 54.8 ± 11.73 |
| Sex: Female, Male(Participants) | Trastuzumab Deruxtecan (T-DXd) | Trastuzumab+Capecitabine | Lapatinib+Capecitabine | Total |
|---|---|---|---|---|
| Female | 403 | 89 | 111 | 603 |
| Male | 3 | 2 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Trastuzumab Deruxtecan (T-DXd) | Trastuzumab+Capecitabine | Lapatinib+Capecitabine | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 122 | 20 | 36 | 178 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 10 | 2 | 5 | 17 |
| White | 257 | 66 | 61 | 384 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 15 | 3 | 8 | 26 |
| Region of Enrollment(participants) | Trastuzumab Deruxtecan (T-DXd) | Trastuzumab+Capecitabine | Lapatinib+Capecitabine | Total |
|---|---|---|---|---|
| United States | 41 | 14 | 9 | 64 |
| Czechia | 1 | 2 | 0 | 3 |
| Japan | 46 | 6 | 18 | 70 |
| United Kingdom | 27 | 4 | 4 | 35 |
| Spain | 29 | 8 | 7 | 44 |
| Greece | 9 | 3 | 2 | 14 |
| South Korea | 66 | 11 | 17 | 94 |
| Turkey | 36 | 12 | 4 | 52 |
| Belgium | 4 | 1 | 0 | 5 |
| Brazil | 41 | 10 | 8 | 59 |
| Italy | 33 | 3 | 17 | 53 |
| Israel | 14 | 0 | 4 | 18 |
| France | 37 | 8 | 12 | 57 |
| Australia | 10 | 7 | 4 | 21 |
| Germany | 12 | 2 | 5 | 19 |
Showing the first 100 of 227 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Aug 2018 to primary completion in Jun 2022, 46 months.
Results were first posted in Jun 2023, 11 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 46 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan